Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Biological Basis of Therapy for Negative Symptom Spectrum Disorders: Risperdal Effect on Frontal Metabolism in Asperger's Disorder

NCT00352196 is registered in ClinicalTrials.gov with Augusta University as lead sponsor.

NCT NCT00352196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00352196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Biological Basis of Therapy for Negative Symptom Spectrum Disorders: Risperdal Effect on Frontal Metabolism in Asperger's Disorder
Lead sponsor
Augusta University
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2001
Completion date
May 31, 2007
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asperger's disorder